All News
Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732
Sosei Group Corporation (“the Company”; TSE: 4565), the world-leader in GPCR-focused structure-based drug design (SBDD) and development, and Cancer Research UK, the world’s largest independent funder of cancer research, today announce that the first patient has been dosed in a Phase I/IIa clinical trial evaluating Sosei Heptares’ orally available small molecule cancer immunotherapy drug HTL0039732 for advanced solid tumors.
Meiji Seika Pharma Announces Positive Results in Phase II Study of ME3183, a Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Moderate-to-Severe Plaque Psoriasis in the United States and Canada
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi) today announced that ME3183, a novel highly-potent selective phosphodiesterase-4 (PDE4) inhibitor, met the primary endpoint based on “PASI-75”, defined as the proportion of subjects achieving 75% improvement in Psoriasis Area Severity Index (PASI), in phase II clinical trial in patients with moderate-to-severe plaque psoriasis conducted in the United States and Canada.
Baird Medical Submits Disposable Microwave Ablation Needle and MWA System Application to U.S. FDA for Treatment of Soft Tissue Microwave Ablation
Baird Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China, today announced the 510(k) premarket notification submission of the Company's Disposable Microwave Ablation ("MWA") Needle and the Company's MWA System to the U.S. Food and Drug Administration (FDA) for the treatment of soft tissue microwave ablation.
Lynk Pharmaceuticals Announced Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Atopic Dermatitis
HANGZHOU, China, Aug. 9, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced positive topline data from a Phase II clinical trial of LNK01001 for the treatment of atopic dermatitis.
GenScript Biotech and T-MAXIMUM Biotech Form Strategic Alliance on cGMP sgRNA
PISCATAWAY, N.J. and NANJING, China, Aug. 9, 2023 /PRNewswire/ -- GenScript Biotech, the world's leading life-science research tools and services provider, and T-MAXIMUM Biotech, a biotechnology company pioneering universal cell therapies, have formed a strategic collaboration agreement to enable the development of T-MAXIMUM's development CAR-T cell therapy using GenScript's CRISPR nucleic acid reagents.
Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer’s Disease Treatment ADLARITY® in Multiple Markets Across Asia
BOSTON & TAIPEI, Taiwan--(BUSINESS WIRE)--Corium, LLC (“Corium”), a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Lotus Pharmaceutical (1795:TT; “Lotus”), a multinational pharmaceutical company, announced that the companies have entered into an exclusive Collaboration and License Agreement for ADLARITY® (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in ten markets across Asia.
ALR Technologies Announces Canadian Launch Plans for the GluCurve Pet CGM
ALR Technologies SG Ltd. (“ALRT” or the “Company”) (OTCQB:ALRTF), the diabetes management company, announces plans to launch the GluCurve Pet CGM (“GluCurve”) in Canada during Q3 2023 with a direct to veterinarian clinic sales model through GluCurve.ca.
Game-changing Indian MRI Scanner Launched: Targets 6 billion People without Access to Cutting-edge Imaging Technologies
India-based company Voxelgrids has launched an advanced and affordable MRI scanner with the potential to revolutionize healthcare accessibility not only in India but also worldwide.
Adlai Norty has filed F-1 with the US SEC for the company to be listed in the US in late July
Adlai Nortye, headquartered in Hangzhou, China and with an office in New Jersey, USA, has filed F-1 with the US SEC for the company to be listed in the US in late July. Cantor is the lead underwriter and CLSA is a co-manager
上海打响“医保支持医药创新”第一枪，全国会否跟进？
Shanghai Municipal Medical Insurance Bureau and seven other departments jointly issued policies for Shanghai to further improve the diversified payment mechanism. Shanghai has become the first province to use medical insurance policies to support pharmaceutical innovation.
